Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,034 USD | +0.99% |
|
-1.60% | +17.75% |
07-03 | Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval | MT |
07-03 | Sanofi obtains EU approval for Dupixent | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.75% | 112B | |
+16.61% | 122B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B | |
+125.88% | 11.29B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-07-2019 10